Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

AIM: To evaluate the efficacy and safety of ertugliflozin and sitagliptin co‐administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin. METHODS: In this study (http://Clinicaltrials.gov NCT02099110), patients with glycated haemoglobin (Hb...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Obes Metab
Asıl Yazarlar: Pratley, Richard E., Eldor, Roy, Raji, Annaswamy, Golm, Gregory, Huyck, Susan B., Qiu, Yanping, Sunga, Sheila, Johnson, Jeremy, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947297/
https://ncbi.nlm.nih.gov/pubmed/29266675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13194
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller